Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2020-05-06 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the progress of its share repurchase program through centralized bidding transactions. It details the number of shares repurchased, the price range, total funds used, and references the board and shareholder meetings approving the buyback plan. The document is short (1166 characters) and focuses on the update of the share buyback activity, not a full financial report or earnings release. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2020-05-06 Chinese
关于使用部分暂时闲置募集资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the progress of using temporarily idle raised funds to purchase financial products. It includes specifics about the entrusted financial products, amounts, risk control measures, approval procedures, and financial impacts. The document references regulatory approvals from the China Securities Regulatory Commission and Shanghai Stock Exchange, and provides detailed financial data and risk disclosures. It is not a full annual or interim report, nor an earnings release or management discussion. It is a specific update on capital management activities related to fundraising proceeds, focusing on the use of idle raised funds for purchasing financial products. This fits the definition of a Capital/Financing Update (CAP) as it updates on company fundraising and capital usage activities. The document length and detail confirm it is not a mere announcement of a report (RPA) or a regulatory filing (RNS). Therefore, the correct classification is CAP with high confidence.
2020-04-22 Chinese
关于使用部分闲置自有资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Kunming Pharmaceutical Corporation regarding the progress of using part of its idle funds to purchase wealth management products. It includes specifics about the entrusted financial products, amounts, expected yields, risk control measures, and the impact on the company. The document is not a full financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is a regulatory announcement about the company's capital management activities, specifically about investment in financial products. This fits best under the category of Capital/Financing Update (CAP), as it relates to updates on company financing activities and capital usage. The document length is sufficient and contains substantive details about the financing activity, not just a brief notice or certification. Therefore, the classification is CAP with high confidence.
2020-04-22 Chinese
关于回购注销部分限制性股票通知债权人的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the repurchase and cancellation of a portion of restricted shares due to certain incentive plan participants no longer meeting conditions. It details the legal basis for notifying creditors about the reduction in registered capital and provides instructions for creditors to submit claims. The document references prior board and shareholder approvals and includes procedural information for creditors. It is not a financial report, earnings release, or management discussion but a formal notification related to share repurchase and capital reduction. This fits the category of Transaction in Own Shares (POS), which covers company buybacks or cancellations of its own shares.
2020-04-20 Chinese
2019年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a 2019 Annual General Meeting (AGM) resolution announcement for Kunming Pharmaceutical Group Co., Ltd. It details the date and location of the AGM, attendance of shareholders and board members, and the voting results on various proposals including the 2019 annual reports, financial statements, profit distribution, and other corporate matters. The document primarily reports the resolutions passed at the AGM and the voting outcomes, rather than presenting the full annual report or financial statements themselves. It is a formal announcement of the AGM decisions and voting results, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 5082 characters, which is sufficient for a detailed voting result announcement but does not contain the full annual report or financial data. Therefore, the correct classification is DVA with high confidence.
2020-04-20 Chinese
2019年年度股东大会的法律意见
AGM Information Classification · 95% confidence The document is a legal opinion from a law firm regarding the procedures, attendance, and resolutions of the 2019 Annual General Meeting (AGM) of Kunming Pharmaceutical Group Co., Ltd. It details the convening, attendance, voting procedures, and results of the AGM. The content focuses on the AGM event itself rather than the full annual report or financial statements. The document length is short (1565 characters), and it is clearly a legal opinion related to the AGM, not the AGM materials or presentations. Therefore, it fits best under AGM Information (AGM-R), which covers presentations and materials shared during the AGM or related official documents about the AGM.
2020-04-20 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.